Amarillo Biosciences plans phase 2 study of interferon alpha lozenges in oral warts

By Lisa Kerner

Erie, Pa., May 23 - Amarillo Biosciences, Inc. said it submitted a protocol to the Food and Drug Administration for a phase 2 study to test low-dose interferon alpha lozenges administered orally to human immunodeficiency virus-positive subjects with oral warts, common in HIV-infected patients and possibly a sign of disease progression.

Human papilloma viruses, one cause of oral lesions, induce hyperplastic lesions in the soft tissue such as papillomas, warts, condylomata and focal epithelial hyperplasia, according to a company news release.

Current treatment includes cryosurgery, electrocoagulation, CO2 laser and excision, all with a high rate of recurrence.

Amarillo Biosciences said two previous studies demonstrated the interferon alpha lozenges' ability to reduce oral wart load in HIV-positive patients.

Should the new study demonstrate the efficacy and safety of this treatment regimen, ABI plans to conduct a phase 3 study followed by the filing of a new drug application with the FDA.

The FDA has granted orphan drug status to Amarillo Biosciences for natural human lymphoblastoid interferon-alpha in the treatment of papilloma virus warts in the oral cavity of HIV-positive patients.

Amarillo Biosciences is a biotechnology firm located in Amarillo, Texas.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.